Akero Therapeutics Inc [AKRO] stock prices are up 1.83% to $25.60 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AKRO shares have gain 13.12% over the last week, with a monthly amount drifted -16.37%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Akero Therapeutics Inc [NASDAQ: AKRO] stock has seen the most recent analyst activity on November 18, 2024, when Citigroup initiated its Buy rating and assigned the stock a price target of $65. On September 19, 2023, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $69 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $83 on August 28, 2023. Morgan Stanley upgraded its rating to a Overweight and raised its price target to $65 on January 27, 2023. Evercore ISI upgraded its rating to Outperform for this stock on September 14, 2022, and upped its price target to $50. In a note dated October 19, 2021, Morgan Stanley downgraded an Equal-Weight rating on this stock but restated the target price of $27.
The stock price of Akero Therapeutics Inc [AKRO] has been fluctuating between $15.32 and $37.00 over the past year. Currently, Wall Street analysts expect the stock to reach $50 within the next 12 months. Akero Therapeutics Inc [NASDAQ: AKRO] shares were valued at $25.60 at the most recent close of the market. An investor can expect a potential return of 95.31% based on the average AKRO price forecast.
Analyzing the AKRO fundamentals
Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -948.14%, Pretax Profit Margin comes in at -835.29%, and Net Profit Margin reading is -835.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.33 and Total Capital is -0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.17 points at the first support level, and at 24.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.12, and for the 2nd resistance point, it is at 26.63.
Ratios To Look Out For
It’s worth pointing out that Akero Therapeutics Inc [NASDAQ:AKRO]’s Current Ratio is 17.25. In addition, the Quick Ratio stands at 17.25 and the Cash Ratio stands at 7.3.
Transactions by insiders
Recent insider trading involved Young Jonathan, Chief Operating Officer, that happened on Jan 02 ’25 when 10000.0 shares were sold. Officer, Jonathan Young completed a deal on Jan 02 ’25 to buy 70000.0 shares. Meanwhile, Senior VP, Commercial Strategy Lamy Patrick sold 1000.0 shares on Dec 16 ’24.
